New Concerns of a Potentially Serious Adverse Event with Oral Capecitabine
January 8th 2014In an important change to the prescribing information of Xeloda (capecitabine), Hoffman-La Roche, in cooperation with Health Canada, released an advisory on the potential for Stevens-Johnson syndrome and toxic epidermal necrolysis with use of the oral chemotherapy agent.
Read More
UBC Researchers Deal a Major Blow to a Controversial Theory of Multiple Sclerosis Pathology
January 7th 2014The controversial chronic cerebrospinal venous insufficiency theory states that constricted vasculature is part of the pathophysiology of multiple sclerosis. A recent trial shows that the theory may be a scientific dead end.
Read More
Multiple Sclerosis: Changes in Epidemiology and Gaps in Patient Access
December 31st 2013An update to the Atlas of Multiple Sclerosis (MS) shows a modest increase in the number of patients with MS and the prevalence of MS between 2008 and 2013. The report also highlights disparities in access to treatment between high- and low-income countries.
Read More
Researchers in the Netherlands found that improvements in diagnostic testing, new treatments, and better management may be responsible for improvements in physical disability, anxiety, and depression ratings over the past 20 years ago in patients with rheumatoid arthritis.
Read More
Are Patients Taking Oral Cancer Regimens as Prescribed?
September 23rd 2013Between 21% and 28% of patients taking an oral therapy for hepatocellular carcinoma (HCC) were nonadherent to treatment. Certain groups of patients may benefit from counseling services that promote improved adherence.
Read More